(Q38041019)

27 August 2017

Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature (English)

1 reference

27 August 2017

1 reference

1 reference

1 reference

1 reference

5

Stephen S Roberts

1 reference

27 August 2017

Brian H Kushner

1

1 reference

27 August 2017

Shakeel Modak

2

1 reference

27 August 2017

Kim Kramer

3

1 reference

27 August 2017

Ellen M Basu

4

1 reference

27 August 2017

Nai-Kong V Cheung

6

1 reference

27 August 2017

language of work or name

English

0 references

publication date

5 September 2012

1 reference

27 August 2017

1 reference

27 August 2017

119

1 reference

27 August 2017

3

1 reference

27 August 2017

665-671

1 reference

Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study

27 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Chemotherapy for patients with recurrent or refractory neuroblastoma: a POG Phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Did salvage ICE chemotherapy improve the outcome in primary resistant/relapsing stage III/IV neuroblastoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d'Oncologie Pédiatrique

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Ifosfamide encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

7 January 2021

High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

7 January 2021

Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

7 January 2021

High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

7 January 2021

Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

7 January 2021

Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

7 January 2021

Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27783

7 January 2021

Identifiers

DOI

10.1002/CNCR.27783

1 reference

27 August 2017

1 reference